What is the average lead time for orders?

The peak season lead time is approximately one month.

What is the application and usage mode?

It is an IV Injectable solution used for Internal Medicine, suitable for elderly, children, and adults.

What are the main commercial terms?

International commercial terms include FOB, CFR, CIF, CIP, and EXW.

Compound Ringer Lactate Solution Injection Infusion

Name: Compound Ringer Lactate Solution Injection Infusion
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 877298955

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.20-0.40

10,000 Pieces

Sample price:US$0.00/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

IV Injectable

Model NO.

1000ml

Suitable for

Elderly, Children, Adult

State

Liquid

Shape

Solution

Type

Organic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Drug Reg./Approval No.

H20044961

Production Line

GMP Approved

Transport Package

30 Bottles/Carton

Specification

500ml

Trademark

SHIMEN

Origin

China

Key features

GMP Approved Production: Manufactured in strict accordance with GMP requirements on automated production lines.

Comprehensive Composition: Contains sodium lactate, sodium chloride, potassium chloride, calcium chloride, and water.

Trusted Manufacturer: Shijiazhuang No.4 Pharmaceutical Co.,Ltd. has 70 years of history and is a top 100 enterprise.

Global Export Reach: Products exported to over 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Advanced Technology: Production lines feature full automation and information control at international advanced levels.

Versatile Application: Suitable for elderly, children, and adults as an IV Injectable solution for internal medicine.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤15hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.